利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

93 records (took 0.03 seconds)

    COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS
    6.
    发明申请
    COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS 审中-公开
    组合物及其使用方法

    公开(公告)号：US20160250173A1

    公开(公告)日：2016-09-01

    申请号：US15154100

    申请日：2016-05-13

    Applicant: Biosuccess Biotech Co. Ltd.

    Inventor： Hung-Fong CHEN ,  Zheng Tao HAN

    IPC: A61K31/225 ,  A61K45/06

    CPC classification number: A61K31/225 ,  A61K31/216 ,  A61K31/22 ,  A61K31/381 ,  A61K31/55 ,  A61K31/573 ,  A61K31/603 ,  A61K45/06 ,  A61K2300/00

    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.

    Abstract translation: 提供含有佛波醇酯或佛波醇酯衍生物的方法和组合物用于治疗慢性和急性病症。 这种情况可能是由疾病，症状或后遗症引起的。 慢性和急性病症可能是由于艾滋病毒和艾滋病，肿瘤性疾病中风，肾脏疾病，尿失禁，自身免疫性疾病，帕金森病，前列腺肥大，衰老或这些疾病的治疗等病毒感染。 提供了另外的组合物和方法，其使用佛波醇酯或衍生化合物与至少一种另外的试剂组合，以产生针对哺乳动物受试者的急性和慢性病症的更有效的治疗工具。

    Method of inhibiting the growth of Helicobacter pylori
    8.
    发明授权
    Method of inhibiting the growth of Helicobacter pylori 有权
    抑制幽门螺杆菌生长的方法

    公开(公告)号：US08175860B2

    公开(公告)日：2012-05-08

    申请号：US12473155

    申请日：2009-05-27

    Applicant: Wen-Ching Wang ,  Wen-Chi Cheng ,  Jinn-Moon Yang

    Inventor： Wen-Ching Wang ,  Wen-Chi Cheng ,  Jinn-Moon Yang

    IPC: G06G7/48 ,  G01N33/48 ,  G01N31/00

    CPC classification number: A61K31/635 ,  A61K31/121 ,  A61K31/136 ,  A61K31/155 ,  A61K31/185 ,  A61K31/352 ,  A61K31/404 ,  A61K31/428 ,  A61K31/4425 ,  A61K31/603 ,  A61K31/606 ,  G06F19/16 ,  G06F19/706

    Abstract: A method of identifying a drug candidate to a target protein for inhibiting shikimate pathway comprising (a) performing a molecular program for computing a molecule conformation and orientation relative to an active site of the target protein and selecting top-rank molecules, (b) generating protein-molecule interacting profiles and identifying conserved interactions and pharmacophore spots, (c) developing homologous pharmacophore models for identifying pharmacophore hot spots, (d) rescoring molecules selected from step (a) by their homologous pharmacophore scores, (e) selecting potential molecules having the highest homologous pharmacophore scores, and (f) acquiring corresponding real compounds of the potential molecules selected from step (c) and identifying their inhibitory activity on the target protein by bioassay.

    Abstract translation: 鉴定靶向蛋白质候选药物以抑制莽草酸通路的方法，包括（a）执行分子程序，用于计算相对于靶蛋白的活性位点的分子构象和取向并选择顶级分子，（b）产生 （c）开发用于鉴定药效团热点的同源药效团模型，（d）通过其同源药效团评分来选择步骤（a）中选出的分子，（e）选择具有 最高同源药效团评分，以及（f）获取选自步骤（c）的潜在分子的相应真实化合物，并通过生物测定鉴定其对靶蛋白的抑制活性。

    ANTI-INFECTIVE HYDROXY-PHENYL-BENZOATES AND METHODS OF USE
    9.
    发明申请
    ANTI-INFECTIVE HYDROXY-PHENYL-BENZOATES AND METHODS OF USE 有权
    抗感染性羟基苯甲酸酯及其使用方法

    公开(公告)号：US20120040888A1

    公开(公告)日：2012-02-16

    申请号：US13201447

    申请日：2009-10-26

    Applicant: Michael R. Yeaman ,  Arnold Bayer

    Inventor： Michael R. Yeaman ,  Arnold Bayer

    IPC: A61K31/60 ,  A61K38/14 ,  A61P31/04

    CPC classification number: A61K31/60 ,  A61K31/5377 ,  A61K31/603 ,  A61K38/14 ,  Y02A50/402 ,  Y02A50/47 ,  Y02A50/473 ,  Y02A50/481 ,  Y02A50/483

    Abstract: The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA). The invention also provides a method for preventing or treating an infectious disease caused by of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) or vancomycin-resistant Staphylococcus aureus (VRSA), comprising systemically coadministering in a synergistic combination to a subject in need thereof prophylactically or therapeutically effective amounts, individually or collectively, of a salicylic acid (SAL) or a SAL analogue and at least one additional antimicrobial agent, for example, vancomycin and/or linezolid.

    Abstract translation: 本发明提供了一种预防或治疗由细胞外微生物引起的疾病的方法，所述方法包括向有需要的受试者全身施用预防或治疗有效量的水杨酸（SAL）或SAL类似物。 细胞外微生物可以是细菌属葡萄球菌，例如金黄色葡萄球菌。 细胞外微生物可以是对至少一种抗生素具有抗性的菌株。 该菌株可以选自耐甲氧西林金黄色葡萄球菌（MRSA），万古霉素 - 中间体金黄色葡萄球菌（VISA）和耐万古霉素金黄色葡萄球菌（VRSA）。 本发明还提供了一种预防或治疗由耐甲氧西林金黄色葡萄球菌（MRSA），万古霉素中间体金黄色葡萄球菌（VISA）或万古霉素耐药金黄色葡萄球菌（VRSA）引起的感染性疾病的方法，其包括以协同组合系统地共同施用 （SAL）或SAL类似物和至少一种另外的抗微生物剂例如万古霉素和/或利奈唑胺的预防或治疗有效量的预防或治疗有效量。

Patent Agency Ranking